- Report
- April 2025
- 250 Pages
Global
From €3997EUR$4,490USD£3,493GBP
- Report
- January 2025
- 100 Pages
Global
From €5297EUR$5,950USD£4,628GBP
- Report
- August 2025
- 193 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- October 2025
- 287 Pages
Global
From €5208EUR$5,850USD£4,550GBP
- Report
- September 2025
- 250 Pages
Global
From €3997EUR$4,490USD£3,493GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1424EUR$1,600USD£1,245GBP
€1780EUR$2,000USD£1,556GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €890EUR$1,000USD£778GBP
€1113EUR$1,250USD£972GBP
- Report
- January 2025
- 180 Pages
Global
From €4006EUR$4,500USD£3,500GBP
- Report
- May 2025
- 472 Pages
Global
From €6227EUR$6,995USD£5,441GBP
- Report
- March 2025
- 468 Pages
Global
From €4272EUR$4,799USD£3,733GBP
- Report
- February 2025
- 138 Pages
Global
From €2000EUR$2,407USD£1,809GBP
- Clinical Trials
- July 2025
- 220 Pages
Global
From €2136EUR$2,400USD£1,867GBP
€2671EUR$3,000USD£2,334GBP
- Report
- September 2025
- 180 Pages
Global
From €2136EUR$2,400USD£1,867GBP
€2671EUR$3,000USD£2,334GBP
- Report
- November 2024
- 256 Pages
Global
From €4006EUR$4,500USD£3,500GBP
- Report
- April 2025
- 203 Pages
Global
From €4139EUR$4,650USD£3,617GBP
- Report
- October 2025
Global
From €4362EUR$4,900USD£3,811GBP
- Report
- October 2025
Global
From €4362EUR$4,900USD£3,811GBP
- Report
- June 2025
- 100 Pages
Global
From €4362EUR$4,900USD£3,811GBP
- Report
- April 2025
Global
From €4362EUR$4,900USD£3,811GBP
- Report
- August 2025
Global
From €4407EUR$4,950USD£3,850GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more